Biospecimen Core

生物样本核心

• 批准号: 10493296
• 负责人: Charles V Clevenger
• 金额: $ 16.04万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10493296
• 关键词: Address; Agreement; Artificial Intelligence; Bioinformatics; Biological Specimen Banks; Biometry; Blood specimen; Cancer Center; Cancer Patient; Center for Translational Science Activities; City of Hope Comprehensive Cancer Center; Clinical; Clinical Data; Collaborations; Collection; Confidentiality of Patient Information; Consent; Data; Data Element; Databases; Dedications; Development; Disease; Documentation; Early Detection Research Network; Ensure; European; Excision; Faculty; Formalin; Freezing; Future; Health; Hospital Information Systems; Housing; Human; Individual; Informatics; Institution; Institutional Review Boards; Investigation; Lead; Link; Liquid substance; Malignant Neoplasms; Malignant neoplasm of lung; Massey Cancer Center at the Virginia Commonwealth University; Medical; Molecular; Molecular Analysis; National Cancer Institute; Outcome; Paraffin Embedding; Pathologic; Pathology; Pathology Report; Procedures; Process; Reproducibility; Research; Research Personnel; Research Project Grants; Secure; Site; Source; South Carolina; Specimen; Standardization; Techniques; Technology; Time; Tissue Banks; Tissue Embedding; Tissues; Translational Research; United States National Aeronautics and Space Administration; Universities; Virginia; base; behavioral health; biobank; cancer health disparity; cancer risk; data repository; diversity and inclusion; ethnic minority; health data; high risk; human tissue; programs; racial diversity; racial minority; sample collection; social determinants; social health determinants; survival outcome; translational goal; translational study

BIOSPECIMEN-PATHOLOGY CORE: PROJECT SUMMARY Most biospecimens in the US are collected from individuals of Northern European ancestry, limiting the generalizability of findings. There is an urgent need to increase the availability of high-quality biospecimens from ethnic and racial minorities for translational lung cancer disparities research. A significant goal of the Translational Research Center in Lung Cancer Disparities (TRACER) Biospecimen/Pathology Core (BPC) is to coordinate efforts related to collection, processing, storage, and distribution of annotated human biospecimens for all participating sites and projects, including the a future pilot research projects supported by the Developmental Research Program (DRP). The TRACER BPC team brings together experts with a shared dedication to eradicating disparities, and this union will be formalized by institutional agreements and standard operating procedures (SOPs). The TRACER BPC will provide translational disparities researchers access to an expanded array of biospecimens, analytical techniques, and annotations with clinical data as well as social determinants of health data. The BPC Lead and Co-Leads are established leaders in lung cancer pathology, biorepositories, cancer informatics, geospatial analysis, behavioral health and cancer biologists offering molecular analysis techniques – all committed to disparities and translational research. TRACER BPC specimens will be jointly housed at the Massey Cancer Center at Virginia Commonwealth University VCU), the Hollings Cancer Center at the Medical University South Carolina (MUSC) and the City of Hope Comprehensive Cancer Center. VCU will be the central IRB, andcommon SOPs, data elements, and platforms will be established. VCU will compile and integrate data, and data will be uploaded to the Jet Propulsion Lab (JPL; NASA) server. JPL houses and integrates the Early Detection Research Network (EDRN) data. Housing TRACER data with JPL will facilitate future TRACER-EDRN collaborations. Aim 1 will provide a portal through which TRACER collaborative investigators can acquire through uniform SOP’s the human tissues, fluids, and blood samples for research projects of this P20 with high rigor and reproducibility. Aim 2 will collect and annotate specimens including demographic data, clinical data, histopathologic results, molecular annotation and social determinants of health data. Working with the TRACER Biostatistics and Bioinformatics Core, TRACER investigators will have access to a fully integrated centralized information source. Aim 3 will expand TRACER investigators’ access to cutting-edge technology and artificial intelligence analytics through a partnership with the National Cancer Institute’s Early Detection Research Network (EDRN).

生物标本病理学核心：项目总结